治療抵抗性高血圧患者におけるXXB750の有効性、安全性、忍容性および用量設定試験。

基本情報

NCT ID

NCT05562934

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

189

治験依頼者名

Novartis

概要

The purpose of this 20-week randomized double-blind study in patients with resistant hypertension (rHTN) is to evaluate the efficacy, safety, and tolerability, of different doses of XXB750 administered as subcutaneous (SC) injections, compared to placebo. Since all study participants will be patients with rHTN, all study treatments will be given on top of maximally tolerated background antihypertensive therapy recommended by international guidelines for treatment of HTN (i.e., a thiazide or a thiazide-like diuretic, an angiotensin converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB), and a long-acting dihydropyridine calcium channel blocker (CCB).

対象疾患

介入

依頼者（Sponsor）